<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mov Disord Clin Pract</journal-id><journal-id journal-id-type="iso-abbrev">Mov Disord Clin Pract</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2330-1619</journal-id><journal-id journal-id-type="publisher-id">MDC3</journal-id><journal-title-group><journal-title>Movement Disorders Clinical Practice</journal-title></journal-title-group><issn pub-type="epub">2330-1619</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29780852</article-id><article-id pub-id-type="pmc">5947645</article-id><article-id pub-id-type="doi">10.1002/mdc3.12595</article-id><article-id pub-id-type="publisher-id">MDC312595</article-id><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Articles</subject></subj-group></article-categories><title-group><article-title>Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open&#x02010;label ADS&#x02010;5102</article-title><alt-title alt-title-type="right-running-head">ADS&#x02010;5102 in Previous Amantadine Patients</alt-title><alt-title alt-title-type="left-running-head">S.H. Isaacson et al.</alt-title></title-group><contrib-group><contrib id="mdc312595-cr-0001" contrib-type="author" corresp="yes"><name><surname>Isaacson</surname><given-names>Stuart H.</given-names></name><degrees>MD</degrees><address><email>isaacson@ParkinsonsCenter.org</email></address><xref ref-type="aff" rid="mdc312595-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="mdc312595-cr-0002" contrib-type="author"><name><surname>Fahn</surname><given-names>Stanley</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="mdc312595-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="mdc312595-cr-0003" contrib-type="author"><name><surname>Pahwa</surname><given-names>Rajesh</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="mdc312595-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="mdc312595-cr-0004" contrib-type="author"><name><surname>Tanner</surname><given-names>Caroline M.</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="mdc312595-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="mdc312595-cr-0005" contrib-type="author"><name><surname>Espay</surname><given-names>Alberto J.</given-names></name><degrees>MD, MSc</degrees><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3389-136X</contrib-id><xref ref-type="aff" rid="mdc312595-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="mdc312595-cr-0006" contrib-type="author"><name><surname>Trenkwalder</surname><given-names>Claudia</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="mdc312595-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="mdc312595-cr-0007" contrib-type="author"><name><surname>Adler</surname><given-names>Charles H.</given-names></name><degrees>MD, PhD</degrees><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1045-2743</contrib-id><xref ref-type="aff" rid="mdc312595-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="mdc312595-cr-0008" contrib-type="author"><name><surname>Patni</surname><given-names>Rajiv</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="mdc312595-aff-0008">
<sup>8</sup>
</xref></contrib><contrib id="mdc312595-cr-0009" contrib-type="author"><name><surname>Johnson</surname><given-names>Reed</given-names></name><degrees>BS</degrees><xref ref-type="aff" rid="mdc312595-aff-0008">
<sup>8</sup>
</xref></contrib></contrib-group><aff id="mdc312595-aff-0001">
<label><sup>1</sup></label>
<institution>Parkinson's Disease and Movement Disorders Center of Boca Raton</institution>
<named-content content-type="city">Boca Raton</named-content>
<named-content content-type="country-part">FL</named-content>
<country country="US">USA</country>
</aff><aff id="mdc312595-aff-0002">
<label><sup>2</sup></label>
<institution>Columbia University</institution>
<named-content content-type="city">New York</named-content>
<named-content content-type="country-part">NY</named-content>
<country country="US">USA</country>
</aff><aff id="mdc312595-aff-0003">
<label><sup>3</sup></label>
<institution>University of Kansas Medical Center</institution>
<named-content content-type="city">Kansas City</named-content>
<named-content content-type="country-part">KS</named-content>
<country country="US">USA</country>
</aff><aff id="mdc312595-aff-0004">
<label><sup>4</sup></label>
<institution>University of California, San Francisco and San Francisco Veterans Affairs Medical Center</institution>
<named-content content-type="city">San Francisco</named-content>
<named-content content-type="country-part">CA</named-content>
<country country="US">USA</country>
</aff><aff id="mdc312595-aff-0005">
<label><sup>5</sup></label>
<named-content content-type="organisation-division">Gardner Center for Parkinson's Disease and Movement Disorders</named-content>
<institution>University of Cincinnati</institution>
<named-content content-type="city">Cincinnati</named-content>
<named-content content-type="country-part">OH</named-content>
<country country="US">USA</country>
</aff><aff id="mdc312595-aff-0006">
<label><sup>6</sup></label>
<named-content content-type="organisation-division">Paracelsus&#x02010;Elena&#x02010;Klinik, Kassel and Clinic Neurosurgery</named-content>
<institution>University Medical Center</institution>
<named-content content-type="city">Goettingen</named-content>
<country country="DE">Germany</country>
</aff><aff id="mdc312595-aff-0007">
<label><sup>7</sup></label>
<institution>Mayo Clinic College of Medicine</institution>
<named-content content-type="city">Scottsdale</named-content>
<named-content content-type="country-part">AZ</named-content>
<country country="US">USA</country>
</aff><aff id="mdc312595-aff-0008">
<label><sup>8</sup></label>
<institution>Adamas Pharmaceuticals</institution>
<named-content content-type="city">Emeryville</named-content>
<named-content content-type="country-part">CA</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence to</bold>: Dr. Stuart H. Isaacson, 951 NW 13th Street, Bldg. 5&#x02010;E, Boca Raton, FL 33486; E&#x02010;mail: <email>isaacson@ParkinsonsCenter.org</email></corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>2</month><year>2018</year></pub-date><pub-date pub-type="ppub"><season>Mar-Apr</season><year>2018</year></pub-date><volume>5</volume><issue>2</issue><issue-id pub-id-type="doi">10.1002/mdc3.2018.5.issue-2</issue-id><fpage>183</fpage><lpage>190</lpage><history><date date-type="received"><day>18</day><month>10</month><year>2017</year></date><date date-type="rev-recd"><day>09</day><month>1</month><year>2018</year></date><date date-type="accepted"><day>20</day><month>1</month><year>2018</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2018 International Parkinson and Movement Disorder Society <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2018 The Authors. Movement Disorders Clinical Practice published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:MDC3-5-183.pdf"/><abstract><title>Abstract</title><sec id="mdc312595-sec-0001"><title>Background</title><p>ADS&#x02010;5102 (amantadine) extended release capsules (GOCOVRI&#x02122;) are a treatment for dyskinesia in patients with Parkinson's disease (PD). ADS&#x02010;5102 reduced dyskinesia and OFF time in phase 3 controlled trials of up to six months. Amantadine immediate release (IR) is used for dyskinesia, but suboptimal durability and tolerability limit its clinical utility.</p></sec><sec id="mdc312595-sec-0002"><title>Methods</title><p>In an ongoing, open&#x02010;label, phase 3 study in the US and Western Europe (NCT02202551), patients with PD received 274 mg of ADS&#x02010;5102 (equivalent to 340 mg amantadine HCl) once daily at bedtime for up to two years. Study outcomes included safety and assessment of motor complications, as measured by the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS&#x02010;UPDRS) Part IV. This manuscript focuses on those patients switched to ADS&#x02010;5102 from amantadine IR. Results in two groups of patients who previously completed a randomized controlled trial (EASE LID or EASE LID 3) are also presented according to use of ADS&#x02010;5102 or placebo in that study before enrollment in the open&#x02010;label study.</p></sec><sec id="mdc312595-sec-0003"><title>Results</title><p>Change in MDS&#x02010;UPDRS Part IV at week 8 was &#x02013;0.3 in the previous ADS&#x02010;5102 subgroup (<italic>n =</italic> 61), &#x02013;3.4 in the previous placebo subgroup (<italic>n =</italic> 79), and &#x02013;3.4 in the previous amantadine IR subgroup (<italic>n =</italic> 32). Effects were maintained to week 64. In the previous amantadine IR subgroup (mean treatment duration, 2.5 years), mean amantadine IR dose was 221 mg. Safety data were consistent with previous randomized controlled trials of ADS&#x02010;5102.</p></sec><sec id="mdc312595-sec-0004"><title>Conclusion</title><p>These open&#x02010;label data suggest ADS&#x02010;5102 provides incremental reduction from baseline in MDS&#x02010;UDPRS Part IV score in patients switched directly from amantadine IR, without exacerbating adverse events.</p></sec></abstract><kwd-group><kwd id="mdc312595-kwd-0001">dyskinesia</kwd><kwd id="mdc312595-kwd-0002">amantadine</kwd><kwd id="mdc312595-kwd-0003">Parkinson's disease</kwd><kwd id="mdc312595-kwd-0004">levodopa&#x02010;induced (5 max)</kwd></kwd-group><funding-group><award-group><funding-source>Adamas Pharmaceuticals, Inc.
</funding-source></award-group></funding-group><counts><fig-count count="4"/><table-count count="3"/><page-count count="8"/><word-count count="4412"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>mdc312595</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>March/April 2018</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.3.8.2 mode:remove_FC converted:11.05.2018</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group><fn id="mdc312595-note-0001"><p>
<bold>Funding informaton</bold>: This study was funded by Adamas Pharmaceuticals, Inc.</p></fn><fn id="mdc312595-note-0002"><p>Relevant disclosures and conflicts of interest are listed at the end of this article.</p></fn></fn-group></notes></front><body><sec id="mdc312595-sec-0005"><title>Introduction</title><p>Parkinson's disease (PD) is a progressive synucleinopathy and the second most common neurodegenerative disease in the US.<xref rid="mdc312595-bib-0001" ref-type="ref">1</xref> Cardinal motor symptoms of PD are bradykinesia, rigidity, tremor, and postural instability that reflect reduced striatal dopamine resulting from progressive degeneration of dopaminergic neurons in the substantia nigra.<xref rid="mdc312595-bib-0002" ref-type="ref">2</xref>, <xref rid="mdc312595-bib-0003" ref-type="ref">3</xref> The dopamine precursor levodopa exerts robust efficacy for the motor symptoms of PD.<xref rid="mdc312595-bib-0004" ref-type="ref">4</xref> However, this effect is complicated by the emergence of motor complications (including motor fluctuations [OFF] and dyskinesia).<xref rid="mdc312595-bib-0005" ref-type="ref">5</xref>, <xref rid="mdc312595-bib-0006" ref-type="ref">6</xref>
</p><p>Motor complications are reported by approximately 40% to 60% of patients after five years of levodopa therapy and by nearly all patients (90%) after 10 years.<xref rid="mdc312595-bib-0005" ref-type="ref">5</xref> These motor complications are associated, among others, with impaired activities of daily living, decreased health&#x02010;related quality of life, increased healthcare utilization, increased caregiver burden, and falls.<xref rid="mdc312595-bib-0007" ref-type="ref">7</xref>, <xref rid="mdc312595-bib-0008" ref-type="ref">8</xref> Strategies to improve OFF time include increasing the dosage of levodopa and/or adding adjunctive medications, including enzymatic inhibitors (monoamine oxidase B, catechol&#x02010;<italic>O</italic>&#x02010;methyltransferase) and dopamine agonists, but such strategies can be limited by the emergence of dyskinesia.<xref rid="mdc312595-bib-0009" ref-type="ref">9</xref> Nonsurgical treatments for dyskinesia remain an unmet need. The main strategies for managing dyskinesia in patients with PD include fractionating the levodopa dose, lowering the overall dose of dopaminergic agents as a further treatment option, and lowering the levodopa dose while adding a longer&#x02010;acting dopamine agonist, all of which have the potential to worsen the patient's PD symptoms or increase dyskinesias.<xref rid="mdc312595-bib-0009" ref-type="ref">9</xref>
</p><p>Amantadine is an <italic>N</italic>&#x02010;methyl&#x02010;<sc>d</sc>&#x02010;aspartate (NMDA) receptor antagonist that has uncompetitive binding, blocking only the activated, open&#x02010;channel NMDA receptor.<xref rid="mdc312595-bib-0010" ref-type="ref">10</xref> Amantadine immediate release (IR) was originally approved for influenza, with an additional indication for parkinsonism in 1970.<xref rid="mdc312595-bib-0011" ref-type="ref">11</xref>, <xref rid="mdc312595-bib-0012" ref-type="ref">12</xref> Initially Schwab (1969)<xref rid="mdc312595-bib-0013" ref-type="ref">13</xref> and Parkes (1970)<xref rid="mdc312595-bib-0014" ref-type="ref">14</xref> found that while 200 mg daily of amantadine hydrochloride IR (equivalent to 161 mg amantadine) can be well tolerated, higher doses may be more efficacious yet associated with a greater incidence of central nervous system side effects, especially hallucinations and sleep disruptions. While the NMDA&#x02010;receptor antagonism of amantadine IR has been used to treat dyskinesia, its suboptimal durability and tolerability have limited its clinical utility.<xref rid="mdc312595-bib-0015" ref-type="ref">15</xref>, <xref rid="mdc312595-bib-0016" ref-type="ref">16</xref> Despite the same body of trial evidence, there are differing recommendations for amantadine across the guidelines of various countries.<xref rid="mdc312595-bib-0017" ref-type="ref">17</xref>, <xref rid="mdc312595-bib-0018" ref-type="ref">18</xref>
</p><p>ADS&#x02010;5102 (amantadine) extended release capsules (GOCOVRI&#x02122;), a novel formulation of amantadine, were designed to deliver a distinct concentration&#x02010;time profile of amantadine that is not achievable with amantadine IR. With bedtime dosing of ADS&#x02010;5102, its initial slow rise in plasma concentration overnight achieves twice the plasma level (&#x0223c;1500 ng/mL) of a standard dose of amantadine IR, 100 mg bid during the early morning and throughout the day.<xref rid="mdc312595-bib-0019" ref-type="ref">19</xref> The once&#x02010;daily dosing regimen of ADS&#x02010;5102 may also provide enhanced convenience compared with multiple dosing of amantadine IR.</p><p>Recently, two phase 3, double&#x02010;blind, placebo&#x02010;controlled efficacy studies demonstrated that ADS&#x02010;5102 significantly reduced dyskinesia, with a secondary benefit of reduction in OFF time, when administered once daily at bedtime.<xref rid="mdc312595-bib-0020" ref-type="ref">20</xref>, <xref rid="mdc312595-bib-0021" ref-type="ref">21</xref>, <xref rid="mdc312595-bib-0022" ref-type="ref">22</xref> In the current analysis, we assess the tolerability and efficacy of open&#x02010;label ADS&#x02010;5102 (amantadine) extended release capsules in the subgroup of patients who were receiving amantadine IR and then directly switched to ADS&#x02010;5102 at enrollment in the EASE LID 2 open&#x02010;label study. For comparison, results in two groups of patients who previously completed a randomized controlled trial (EASE LID or EASE LID 3), defined according to their use of ADS&#x02010;5102 or placebo prior to enrollment, are also presented.</p></sec><sec id="mdc312595-sec-0006"><title>Methods</title><p>Between July 28, 2014, and March 10, 2016, patients were screened and evaluated for eligibility in an open&#x02010;label trial of ADS&#x02010;5102 for the treatment of dyskinesia in patients with PD (EASE LID 2). An interim analysis was performed with a data cut&#x02010;off date of December 2, 2016 to evaluate the safety and tolerability of ADS&#x02010;5102. Each site's institutional review board, research ethics board, or independent ethics committee approved study protocol and patient consent forms. All patients provided written informed consent prior to any study procedures.</p><p>Patients were recruited after completing participation in one of the ADS&#x02010;5102 controlled, double&#x02010;blind trials (EASE LID<xref rid="mdc312595-bib-0020" ref-type="ref">20</xref> or EASE LID 3<xref rid="mdc312595-bib-0022" ref-type="ref">22</xref>), or the dose&#x02010;finding EASED study.<xref rid="mdc312595-bib-0021" ref-type="ref">21</xref> Patients who were ineligible to enroll in an ADS&#x02010;5102 trial because they had undergone deep brain stimulation (DBS) were recruited to this open&#x02010;label trial. A full review of the methods and study results from this protocol have been previously published.<xref rid="mdc312595-bib-0023" ref-type="ref">23</xref>
</p><p>This analysis is focused on the subgroup of patients in the EASE LID 2 open&#x02010;label study who were receiving amantadine IR at enrollment (confirmed through review of medication logs) and were switched at enrollment/baseline to ADS&#x02010;5102 (&#x0201c;previous amantadine IR subgroup&#x0201d;). Published study data from EASE LID 2 trial patients who received ADS&#x02010;5102 (&#x0201c;previous active&#x0201d;) or placebo (&#x0201c;previous placebo&#x0201d;) in the preceding randomized&#x02010;controlled studies and enrolled in the open&#x02010;label trial were included in this analysis to provide context (see Fig. <xref rid="mdc312595-fig-0001" ref-type="fig">1</xref>). Previous data for DBS patients is not available as these patients were not eligible for previous ADS&#x02010;5102 phase 3 studies.</p><fig fig-type="Figure" xml:lang="en" id="mdc312595-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Enrollment and subgroup overview.</p><p>Abbreviations: AMT IR, amantadine immediate release; DBS, deep brain stimulation.</p></caption><graphic id="nlm-graphic-1" xlink:href="MDC3-5-183-g001"/></fig><sec id="mdc312595-sec-0007"><title>Statistical Analyses</title><p>All patients who received at least one dose of study drug during the open&#x02010;label study of ADS&#x02010;5102 were included in the safety analysis. All patients who received at least one dose of study drug and provided at least one post&#x02010;baseline Movement Disorder Society&#x02010;Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS&#x02010;UPDRS) assessment were included in the efficacy analysis. Data were summarized by subgroup using descriptive statistics. Changes from baseline were analyzed using a mixed&#x02010;model repeated measure (MMRM) approach with categorical effects for subgroup (i.e., previous active, previous placebo, previous amantadine IR), week (8, 16, 28, 40, 52, and 64), interaction between subgroup and week, and an unstructured variance&#x02010;covariance matrix for repeated random&#x02010;subject effects. To control for known confounders to the changes in MDS&#x02010;UPDRS Part IV, baseline MDS&#x02010;UPDRS Part IV score, age at PD diagnosis, duration of levodopa treatment, duration of dyskinesia, and baseline levodopa dose were included as continuous covariates. Least squares mean (LSM) and <italic>P</italic> values derived from the statistical model are presented.</p></sec></sec><sec id="mdc312595-sec-0008"><title>Results</title><sec id="mdc312595-sec-0009"><title>Patients</title><p>In total, 32 patients were included in the &#x0201c;previous amantadine IR subgroup&#x0201d; at time of EASE LID 2 enrollment: 24 patients were post&#x02010;DBS (average duration 4&#x02013;6 y) and eight patients previously completed the EASED study but had a gap between studies.<xref rid="mdc312595-bib-0021" ref-type="ref">21</xref> Enrollment in EASE LID 2 had been completed when this analysis was performed. Treatment duration and study disposition are shown in Table <xref rid="mdc312595-tbl-0001" ref-type="table-wrap">1</xref> for all subgroups.</p><table-wrap id="mdc312595-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Treatment Duration and Study Disposition</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><thead valign="bottom"><tr valign="bottom" style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">
Previous Active Group<xref ref-type="fn" rid="mdc312595-note-0003">
<sup>a</sup>
</xref>
<break/>
(<italic>n</italic> = 61)</th><th align="left" valign="bottom" rowspan="1" colspan="1">
Previous Placebo Group<xref ref-type="fn" rid="mdc312595-note-0003">
<sup>a</sup>
</xref>
<break/>
(<italic>n</italic> = 79)</th><th align="left" valign="bottom" rowspan="1" colspan="1">
Previous Amantadine IR<xref ref-type="fn" rid="mdc312595-note-0004">
<sup>b</sup>
</xref>
<break/>
(<italic>n</italic> = 32)</th></tr></thead><tbody valign="top"><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" valign="top" rowspan="1" colspan="1">Treatment Duration (days)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Mean (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">419.9 (172.53)</td><td align="left" valign="top" rowspan="1" colspan="1">339.7 (193.38)</td><td align="left" valign="top" rowspan="1" colspan="1">406.8 (218.29)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Median</td><td align="left" valign="top" rowspan="1" colspan="1">389.0</td><td align="left" valign="top" rowspan="1" colspan="1">340.0</td><td align="left" valign="top" rowspan="1" colspan="1">430.0</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Min, Max</td><td align="left" valign="top" rowspan="1" colspan="1">56, 717</td><td align="left" valign="top" rowspan="1" colspan="1">10, 713</td><td align="left" valign="top" rowspan="1" colspan="1">9, 721</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" valign="top" rowspan="1" colspan="1">Disposition</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Ongoing</td><td align="left" valign="top" rowspan="1" colspan="1">46 (75.4)</td><td align="left" valign="top" rowspan="1" colspan="1">48 (60.8)</td><td align="left" valign="top" rowspan="1" colspan="1">17 (53.1)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Completed</td><td align="left" valign="top" rowspan="1" colspan="1">3 (4.9)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (3.8)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (12.5)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Discontinued</td><td align="left" valign="top" rowspan="1" colspan="1">12 (19.7)</td><td align="left" valign="top" rowspan="1" colspan="1">28 (35.4)</td><td align="left" valign="top" rowspan="1" colspan="1">11 (34.4)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Reasons for discontinuation</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" style="padding-left:20%" valign="top" rowspan="1" colspan="1">Adverse Event</td><td align="left" valign="top" rowspan="1" colspan="1">3 (4.9)</td><td align="left" valign="top" rowspan="1" colspan="1">16 (20.3)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (15.6)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" style="padding-left:20%" valign="top" rowspan="1" colspan="1">Consent withdrawn</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">2 (2.5)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" style="padding-left:20%" valign="top" rowspan="1" colspan="1">Unwilling to proceed</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">4 (5.1)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (9.4)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" style="padding-left:20%" valign="top" rowspan="1" colspan="1">Lost to follow up</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">1 (1.3)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (3.1)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" style="padding-left:20%" valign="top" rowspan="1" colspan="1">Needed to take exclusionary medication</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">3 (3.8)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (3.1)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" style="padding-left:20%" valign="top" rowspan="1" colspan="1">eGFR less than 50 mL/min/m<sup>2</sup>
</td><td align="left" valign="top" rowspan="1" colspan="1">1 (1.6)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" style="padding-left:20%" valign="top" rowspan="1" colspan="1">Other</td><td align="left" valign="top" rowspan="1" colspan="1">8 (13.1)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (2.5)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (3.1)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Patients with at least 28 weeks of treatment</td><td align="left" valign="top" rowspan="1" colspan="1">57 (93.4)</td><td align="left" valign="top" rowspan="1" colspan="1">59 (74.7)</td><td align="left" valign="top" rowspan="1" colspan="1">26 (81.3)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Patients with at least 52 weeks of treatment</td><td align="left" valign="top" rowspan="1" colspan="1">32 (52.5)</td><td align="left" valign="top" rowspan="1" colspan="1">37 (46.8)</td><td align="left" valign="top" rowspan="1" colspan="1">20 (62.5)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Patients with at least 76 weeks of treatment<xref ref-type="fn" rid="mdc312595-note-0005">
<sup>c</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">18 (29.5)</td><td align="left" valign="top" rowspan="1" colspan="1">14 (17.7)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (25.0)</td></tr></tbody></table><table-wrap-foot><fn id="mdc312595-note-0003"><p>
<sup>a</sup>These patients were previously enrolled in either EASE LID or EASE LID 3.</p></fn><fn id="mdc312595-note-0004"><p>
<sup>b</sup>Patients with prior DBS (<italic>n</italic> = 24) or who participated in EASED study (<italic>n</italic> = 8).</p></fn><fn id="mdc312595-note-0005"><p>
<sup>c</sup>Study is ongoing.</p></fn><fn id="mdc312595-note-0006"><p>Abbreviations: DBS, deep brain stimulation; eGFR, estimated glomerular filtration rate; IR, immediate release; SD, standard deviation.</p></fn></table-wrap-foot></table-wrap><p>At baseline, the mean reported duration of amantadine IR treatment was 2.5 years (0.1&#x02013;14.4 y) and the mean amantadine IR dose was 221 mg/day, equivalent to 275 mg of amantadine HCl.</p><p>Baseline demographics and PD characteristics are included in Table <xref rid="mdc312595-tbl-0002" ref-type="table-wrap">2</xref>. On average, previous amantadine IR patients were approximately five years younger than patients enrolled directly from the double&#x02010;blind studies (&#x0201c;previous active&#x0201d; and &#x0201c;previous placebo&#x0201d; subgroups; mean age 60.6 y) and predominantly male (68.8%). Mean duration of dyskinesia in previous amantadine IR patients was 7.4 years, compared with 4.6 and 4.0 years in the previous active and previous placebo subgroups, respectively. Baseline MDS&#x02010;UPDRS Part IV scores for previous amantadine IR subgroup were similar to scores of the previous placebo subgroup (&#x0223c;9.5&#x02013;10).<xref rid="mdc312595-bib-0020" ref-type="ref">20</xref>, <xref rid="mdc312595-bib-0022" ref-type="ref">22</xref>
</p><table-wrap id="mdc312595-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Baseline Demographics and PD Characteristics</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><thead valign="bottom"><tr valign="bottom" style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">
Previous Active Group<xref ref-type="fn" rid="mdc312595-note-0008">
<sup>a</sup>
</xref>
<break/>
(<italic>n</italic> = 61)</th><th align="left" valign="bottom" rowspan="1" colspan="1">
Previous Placebo Group<xref ref-type="fn" rid="mdc312595-note-0008">
<sup>a</sup>
</xref>
<break/>
(<italic>n</italic> = 79)</th><th align="left" valign="bottom" rowspan="1" colspan="1">
Previous<break/>
Amantadine IR<xref ref-type="fn" rid="mdc312595-note-0009">
<sup>b</sup>
</xref>
<break/>
(<italic>n</italic> = 32)</th></tr></thead><tbody valign="top"><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" valign="top" rowspan="1" colspan="1">Age (years), Mean (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">64.2 (9.9)</td><td align="left" valign="top" rowspan="1" colspan="1">65.8 (8.8)</td><td align="left" valign="top" rowspan="1" colspan="1">60.6 (11.1)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" valign="top" rowspan="1" colspan="1">Male, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">34 (55.7)</td><td align="left" valign="top" rowspan="1" colspan="1">45 (57.0)</td><td align="left" valign="top" rowspan="1" colspan="1">22 (68.8)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" valign="top" rowspan="1" colspan="1">Years since DBS, Mean (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">n/a</td><td align="left" valign="top" rowspan="1" colspan="1">n/a</td><td align="left" valign="top" rowspan="1" colspan="1">5.8 (4.1)<xref ref-type="fn" rid="mdc312595-note-0010">
<sup>c</sup>
</xref>
</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" valign="top" rowspan="1" colspan="1">Age at PD diagnosis (years), Mean (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">53.4 (10.1)</td><td align="left" valign="top" rowspan="1" colspan="1">56.1 (8.4)</td><td align="left" valign="top" rowspan="1" colspan="1">46.7 (11.4)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" valign="top" rowspan="1" colspan="1">Years since PD diagnosis, Mean (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">11.2 (4.5)</td><td align="left" valign="top" rowspan="1" colspan="1">10.0 (4.1)</td><td align="left" valign="top" rowspan="1" colspan="1">14.5 (7.6)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" valign="top" rowspan="1" colspan="1">Duration of levodopa treatment (years), Mean (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">8.7 (3.7)</td><td align="left" valign="top" rowspan="1" colspan="1">7.8 (4.0)</td><td align="left" valign="top" rowspan="1" colspan="1">10.9 (6.1)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" valign="top" rowspan="1" colspan="1">Baseline levodopa dose, mg/day, Mean (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">805.0 (421.4)</td><td align="left" valign="top" rowspan="1" colspan="1">754.3 (556.2)</td><td align="left" valign="top" rowspan="1" colspan="1">590.3 (359.8)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" valign="top" rowspan="1" colspan="1">
Duration of dyskinesia (years), Mean (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">4.6 (3.4)</td><td align="left" valign="top" rowspan="1" colspan="1">4.0 (2.5)</td><td align="left" valign="top" rowspan="1" colspan="1">7.4 (4.2)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" valign="top" rowspan="1" colspan="1">
Years of prior amantadine exposure, Mean (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">n/a</td><td align="left" valign="top" rowspan="1" colspan="1">n/a</td><td align="left" valign="top" rowspan="1" colspan="1">2.5 (2.9)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" valign="top" rowspan="1" colspan="1">Total daily amantadine IR HCl dose (mg), Mean (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">n/a</td><td align="left" valign="top" rowspan="1" colspan="1">n/a</td><td align="left" valign="top" rowspan="1" colspan="1">275 (81.5)<xref ref-type="fn" rid="mdc312595-note-0011">
<sup>d</sup>
</xref>
</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" valign="top" rowspan="1" colspan="1">MDS&#x02010;UPDRS Part III, Mean (SD) (in ON state)</td><td align="left" valign="top" rowspan="1" colspan="1">21.4 (11.3)</td><td align="left" valign="top" rowspan="1" colspan="1">21.9 (13.1)</td><td align="left" valign="top" rowspan="1" colspan="1">28.1 (13.4)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" valign="top" rowspan="1" colspan="1">MDS&#x02010;UPDRS Part IV Total, Mean (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">6.5 (3.4)</td><td align="left" valign="top" rowspan="1" colspan="1">9.6 (3.1)</td><td align="left" valign="top" rowspan="1" colspan="1">9.8 (3.2)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Item 4.1, Mean (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">1.6 (1.1)</td><td align="left" valign="top" rowspan="1" colspan="1">1.9 (1.1)</td><td align="left" valign="top" rowspan="1" colspan="1">1.9 (0.9)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Item 4.2, Mean (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">0.9 (1.0)</td><td align="left" valign="top" rowspan="1" colspan="1">1.8 (0.9)</td><td align="left" valign="top" rowspan="1" colspan="1">2.2 (0.9)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Item 4.3, Mean (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">0.9 (0.6)</td><td align="left" valign="top" rowspan="1" colspan="1">1.3 (0.6)</td><td align="left" valign="top" rowspan="1" colspan="1">1.2 (0.6)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Item 4.4, Mean (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">1.4 (1.2)</td><td align="left" valign="top" rowspan="1" colspan="1">1.9 (1.3)</td><td align="left" valign="top" rowspan="1" colspan="1">2.1 (1.2)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Item 4.5, Mean (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">1.2 (1.1)</td><td align="left" valign="top" rowspan="1" colspan="1">1.5 (1.1)</td><td align="left" valign="top" rowspan="1" colspan="1">1.4 (1.0)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Item 4.6, Mean (SD)</td><td align="left" valign="top" rowspan="1" colspan="1">0.6 (1.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.9 (1.1)</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 (1.3)</td></tr></tbody></table><table-wrap-foot><fn id="mdc312595-note-0007"><p>Data from patients from the phase 3 study who enrolled into the open&#x02010;label, previously published in Hauser et al.,<xref rid="mdc312595-bib-0023" ref-type="ref">23</xref> are provided for context.</p></fn><fn id="mdc312595-note-0008"><p>
<sup>a</sup>These patients were previously enrolled in either EASE LID or EASE LID 3.</p></fn><fn id="mdc312595-note-0009"><p>
<sup>b</sup>Patients with prior DBS (<italic>n</italic> = 24) or who participated in EASED study (<italic>n</italic> = 8).</p></fn><fn id="mdc312595-note-0010"><p>
<sup>c</sup>Data for patients with prior DBS only (<italic>n</italic> = 24).</p></fn><fn id="mdc312595-note-0011"><p>
<sup>d</sup>Dose 275 (81.5) mg is for amantadine HCl; amantadine dose is 221 mg (range: 100&#x02013;400 mg/day amantadine HCl, equivalent to 81&#x02013;338 mg/day amantadine).</p></fn><fn id="mdc312595-note-0012"><p>Abbreviations: DBS, deep brain stimulation; IR, immediate release; MDS&#x02010;UPDRS, Movement Disorder Society&#x02010;Sponsored Revision of the Unified Parkinson's Disease Rating Scale; PD, Parkinson's disease; SD, standard deviation.</p></fn></table-wrap-foot></table-wrap></sec><sec id="mdc312595-sec-0010"><title>MDS&#x02010;UPDRS</title><p>Fig. <xref rid="mdc312595-fig-0002" ref-type="fig">2</xref>A shows the mean MDS&#x02010;UPDRS Part IV scores over time for all three cohorts. Similar to patients in the previous placebo subgroup, MDS&#x02010;UPDRS Part IV scores in the previous amantadine IR subgroup decreased from baseline to the first post&#x02010;baseline visit (week 8) and were sustained to week 64. At week 8, the LSM treatment difference between the previous amantadine IR subgroup and previous active subgroup was &#x02013;2.8 units (<italic>P</italic> = 0.046), and the LSM treatment difference between the previous placebo and previous active subgroups was &#x02013;2.5 units (<italic>P</italic> = 0.055; Supporting Table 1). The mean percent change from baseline in MDS&#x02010;UPDRS Part IV at week 8 for all subgroups is shown in Fig. <xref rid="mdc312595-fig-0002" ref-type="fig">2</xref>B.</p><fig fig-type="Figure" xml:lang="en" id="mdc312595-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>MDS&#x02010;UPDRS part IV (motor complications) over time. (<bold>A</bold>) Observed changes from baseline in three patient subgroups; (<bold>B</bold>) Mean percentage score reductions from baseline at first post&#x02010;baseline visit (Week 8) in patient subgroups.</p><p>Abbreviations: IR, immediate release; MDS&#x02010;UPDRS, Movement Disorder Society&#x02010;Unified Parkinson's Disease Rating Scale; SE, standard error.</p></caption><graphic id="nlm-graphic-3" xlink:href="MDC3-5-183-g002"/></fig><p>To identify which subscales drove the reduction in Part IV, the mean change from baseline to week 8 were analyzed for each subgroup and the results are shown in Fig. <xref rid="mdc312595-fig-0003" ref-type="fig">3</xref>. The MDS&#x02010;UPDRS Part IV change from baseline to week 8 was &#x02013;0.3 in the previous active subgroup (<italic>n</italic> = 61), &#x02013;3.4 in the previous placebo subgroup (<italic>n</italic> = 79), and &#x02013;3.4 in the previous amantadine IR subgroup (<italic>n</italic>&#x02009;=&#x02009;32). Both the previous placebo and the previous amantadine IR subgroups showed comparable changes in MDS&#x02010;UPDRS Part IV subscale Items 4.1 to 4.4. Fig. <xref rid="mdc312595-fig-0004" ref-type="fig">4</xref>A and Fig. <xref rid="mdc312595-fig-0004" ref-type="fig">4</xref>B show the distribution of change across MDS&#x02010;UPDRS Part IV overall and across its subscales at week 8.</p><fig fig-type="Figure" xml:lang="en" id="mdc312595-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Change from baseline to week 8 in MDS&#x02010;UPDRS Part IV total score and changes in Part IV subscales across patient subgroups.</p><p>No effect was observed in MDS&#x02010;UPDRS Part IV subscale items 4.5 and 4.6 in any patient subgroup.</p><p>Abbreviations: MDS&#x02010;UPDRS, Movement Disorder Society&#x02010;Unified Parkinson's Disease Rating Scale; SD, standard deviation.</p></caption><graphic id="nlm-graphic-5" xlink:href="MDC3-5-183-g003"/></fig><fig fig-type="Figure" xml:lang="en" id="mdc312595-fig-0004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Distribution of change in MDS&#x02010;UPDRS, Part IV (<bold>A</bold>) and subscales (<bold>B</bold>) across patient subgroups at week 8.</p><p>No effect was observed in MDS&#x02010;UPDRS Part IV subscale items 4.5 and 4.6 in any patient subgroup.</p><p>Abbreviations: IR, immediate release; MDS&#x02010;UPDRS, Movement Disorder Society&#x02010;Unified Parkinson's Disease Rating Scale.</p></caption><graphic id="nlm-graphic-7" xlink:href="MDC3-5-183-g004"/></fig><p>Additionally, at the time of the data cut, approximately 25% of patients in each subgroup were able to increase their levodopa dose while on the study (median increase from 225 mg to 325 mg; Supporting Table 2).</p></sec><sec id="mdc312595-sec-0011"><title>Adverse Events</title><p>An overview of adverse events (AEs) is provided in Table <xref rid="mdc312595-tbl-0003" ref-type="table-wrap">3</xref>. In the total study population (<italic>N</italic> = 223), falls, visual hallucination, peripheral edema, and constipation were each reported by &#x02265; 10% of patients; AEs were the primary reason for study&#x02010;drug discontinuation in 32 patients (14.3%). The most common AEs leading to discontinuation (reported by &#x02265; 2% patients) within the previous amantadine IR subgroup were falls (6.3%, <italic>n</italic> = 2). In the overall open&#x02010;label study population, the most common AEs leading to discontinuation were falls (2.2%, <italic>n =</italic> 5), visual hallucinations (2.2%, <italic>n =</italic> 5), and peripheral edema (0.9%, <italic>n =</italic> 2).<xref rid="mdc312595-bib-0023" ref-type="ref">23</xref>
</p><table-wrap id="mdc312595-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>
<italic>Overview of Adverse Events (AEs)</italic> Data from patients from the phase 3 study who enrolled in the open&#x02010;label, previously published in Hauser et al.,<xref rid="mdc312595-bib-0023" ref-type="ref">23</xref> are provided for context.</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000border-bottom:solid 1px #000000" span="1"/><thead valign="bottom"><tr valign="bottom" style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">
Previous Active Group<xref ref-type="fn" rid="mdc312595-note-0013">
<sup>a</sup>
</xref>
<break/>
(<italic>n</italic> = 61)</th><th align="left" valign="bottom" rowspan="1" colspan="1">
Previous Placebo Group<xref ref-type="fn" rid="mdc312595-note-0013">
<sup>a</sup>
</xref>
<break/>
(<italic>n</italic> = 79)</th><th align="left" valign="bottom" rowspan="1" colspan="1">
Previous Amantadine IR<xref ref-type="fn" rid="mdc312595-note-0014">
<sup>b</sup>
</xref>
<break/>
(<italic>n</italic> = 32)</th></tr></thead><tbody valign="top"><tr valign="top" style="border-bottom:solid 1px #000000"><td colspan="4" align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">
<bold>No. (%) of patients with any</bold>
</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">AE</td><td align="char" char="." valign="top" rowspan="1" colspan="1">53 (86.9)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">69 (87.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">27 (84.4)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Study drug&#x02013;related AE</td><td align="char" char="." valign="top" rowspan="1" colspan="1">29 (47.5)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">41 (51.9)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">14 (43.8)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Serious AE (SAE)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">11 (18.0)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">13 (16.5)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">5 (15.6)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Study drug&#x02013;related SAE</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1 (1.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1 (3.1)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td colspan="4" align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">
<bold>No. (%) of patients who permanently discontinued treatment due to any</bold>
</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">AE</td><td align="char" char="." valign="top" rowspan="1" colspan="1">5 (8.2)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">16 (20.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">5 (15.6)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Study drug&#x02013;related AE</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1 (1.6)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">12 (15.2)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">5 (15. 6)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td colspan="4" align="left" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">
<bold>Most common AEs (&#x02265;5% all patients), n (%)</bold>
</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" valign="top" rowspan="1" colspan="1">Fall</td><td align="char" char="." valign="top" rowspan="1" colspan="1">12 (19.7)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">20 (25.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">8 (25.0)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" valign="top" rowspan="1" colspan="1">Visual hallucination</td><td align="char" char="." valign="top" rowspan="1" colspan="1">10 (16.4)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">20 (25.3)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">6 (18.8)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" valign="top" rowspan="1" colspan="1">Peripheral edema</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9 (14.8)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9 (11.4)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">7 (21.9)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" valign="top" rowspan="1" colspan="1">Dizziness</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0</td><td align="char" char="." valign="top" rowspan="1" colspan="1">8 (10.1)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">5 (15.6)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" valign="top" rowspan="1" colspan="1">Constipation</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9 (14.8)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9 (11.4)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">2 (6.3)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" valign="top" rowspan="1" colspan="1">Livedo reticularis</td><td align="char" char="." valign="top" rowspan="1" colspan="1">6 (9.8)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">4 (5.1)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">3 (9.4)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" valign="top" rowspan="1" colspan="1">Nausea</td><td align="char" char="." valign="top" rowspan="1" colspan="1">7 (11.5)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">6 (7.6)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1 (3.1)</td></tr><tr valign="top" style="border-bottom:solid 1px #000000"><td align="left" valign="top" rowspan="1" colspan="1">Dry mouth</td><td align="char" char="." valign="top" rowspan="1" colspan="1">3 (4.9)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">6 (7.6)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1 (3.1)</td></tr></tbody></table><table-wrap-foot><fn id="mdc312595-note-0013"><p>
<sup>a</sup>These patients were previously enrolled in either EASE LID or EASE LID 3.</p></fn><fn id="mdc312595-note-0014"><p>
<sup>b</sup>Patients with prior DBS (<italic>n</italic> = 24) or who participated in EASED study (<italic>n</italic> = 8).</p></fn><fn id="mdc312595-note-0015"><p>Note: A patient was counted once within each preferred term. Percentages were calculated based on the number of patients in each group.</p></fn><fn id="mdc312595-note-0016"><p>Abbreviations: IR, immediate release.</p></fn></table-wrap-foot></table-wrap><p>The incidence of serious AEs (SAEs) was &#x0223c;17% and comparable among the three cohorts; all but two SAEs (urinary tract infection [previous placebo] and suicidal ideation [previous amantadine IR]) were considered not related to study drug. Falls, visual hallucinations, peripheral edema, and dizziness were the most commonly reported AEs in the previous amantadine IR subgroup, consistent with the other subgroups. In general, vital signs and laboratory results remained consistent with baseline values and were similar across all subgroups. In the previous amantadine IR subgroup, there were no reports of orthostatic hypotension or impulse&#x02010;control disorder.</p></sec></sec><sec id="mdc312595-sec-0012"><title>Discussion</title><p>Patients receiving amantadine IR for an average of 2.5 years entered the EASE LID 2 open&#x02010;label study with motor complication scores similar to those of patients previously treated with placebo in the controlled trials. Of the 32 patients receiving amantadine IR who were switched at enrollment, 20 completed at least one year of treatment, 26 completed at least six months, and 17 remain ongoing. After switching from amantadine IR directly to ADS&#x02010;5102 at bedtime (137 mg for one week, 274 mg thereafter), these patients experienced an improvement in motor complications, as shown by a reduction in their MDS&#x02010;UPDRS Part IV scores at the first post&#x02010;baseline visit (week 8). Additionally, more patients were able to increase rather than decrease their levodopa dose (total mg) without compromising dyskinesia control, which would not be expected in a cohort of patients with dyskinesia &#x0003e;4 years' duration.<xref rid="mdc312595-bib-0009" ref-type="ref">9</xref> This treatment effect was also equivalent to that shown in the previous placebo subgroup and was maintained for over a year. The reduction in MDS&#x02010;UPDRS Part IV scores was driven both by decreases in overall time and functional impact of dyskinesia and OFF time.</p><p>The similarity in baseline MDS&#x02010;UPDRS Part IV scores between the Previous Placebo and Previous Amantadine IR group is noteworthy. These patients were enrolled under inclusion criteria that stated that patients could be enrolled who experienced peak dose dyskinesia during screening that might benefit from specific dyskinesia treatment in the judgment of the subject and clinical investigator, or they had a history of peak dose dyskinesia that was currently being managed by amantadine treatment. So, although the reason they were experiencing dyskinesia or motor complications is not known, they were experiencing refractory dyskinesia at entry, despite being on an average of 275 mg amantadine HCl, and most having had DBS.</p><p>The safety profile in patients who switched from amantadine IR directly to ADS&#x02010;5102 was consistent with previously reported safety data from the controlled and open&#x02010;label clinical trials.<xref rid="mdc312595-bib-0023" ref-type="ref">23</xref>
</p><p>The primary limitations of these analyses are the nonrandomized, open&#x02010;label design, and the small sample size of the previous amantadine IR subgroup. The absence of MDS&#x02010;UPDRS, Part III during the OFF state is another limitation. Also, most of the patients in the previous amantadine IR subgroup were status&#x02010;post DBS implantation (<italic>n =</italic> 24; 75%), were younger, and had a longer history of dyskinesia. The MMRM analysis was adjusted for several clinically important baseline covariates. However, the presence of additional unknown and potentially biasing factors cannot be discounted.</p><p>The results seen for the two comparison cohorts (i.e., the small response seen in the previous active subgroup and the improvement in the previous placebo subgroup) are consistent with recent findings from the double&#x02010;blind studies and also support the internal and external validity of the evaluation of the previous amantadine IR group. This indicates that the treatment effect seen in the previous amantadine IR subgroup was not only due to an open&#x02010;label trial effect.</p><p>These open&#x02010;label data are encouraging and support the premise that higher sustained daytime concentrations of amantadine provided by ADS&#x02010;5102 (&#x0223c;1500 ng/mL) provide a further reduction in dyskinesia and OFF time in patients previously treated with amantadine IR. As seen in the other subgroups, this effect was sustained up to 64 weeks. ADS&#x02010;5102 also provided benefits in dyskinesia and OFF in a population already receiving amantadine IR treatment and DBS.</p><p>These data suggest that patients currently being treated with amantadine IR can be switched directly to ADS&#x02010;5102 without interruption. Patients' ability to switch from amantadine IR bid or tid to a once&#x02010;daily regimen of ADS&#x02010;5102 may provide dosing convenience benefits and supports the premise that higher sustained daytime concentrations of amantadine provided by ADS&#x02010;5102 (approx.1500 ng/mL) provide a further reduction in dyskinesia and OFF in previously treated amantadine IR patients.</p></sec><sec id="mdc312595-sec-0013"><title>Author Roles</title><p>1. Research Project: A. Conception, B. Organization, C. Execution;</p><p>2. Statistical Analysis: A. Design, B. Execution, C. Review and Critique;</p><p>3. Manuscript Preparation: A. Writing the First Draft, B. Review and Critique.</p><p>S.H.I.: 1A, 1B, 1C, 2C, 3A, 3B, 3C</p><p>S.F.: 1C, 2C, 3B</p><p>RPah: 1A, 1B, 1C, 2C, 3B</p><p>C.M.T.: 1C, 2C, 3B</p><p>A.J.E.: 1C, 2C, 3B</p><p>C.T.: 1A, 1B, 1C, 2C, 3B</p><p>C.H.A.: 1C, 2C, 3B</p><p>RPat: 1A, 1B, 2A, 2C, 3B</p><p>R.J.: 1A, 1B, 2A, 2C, 3A, 3B</p></sec><sec id="mdc312595-sec-0014"><title>Disclosures</title><p>
<bold>Ethical Compliance Statement</bold>: We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.</p><p>
<bold>Funding Sources and Conflicts of Interest:</bold> This study was funded by Adamas Pharmaceuticals, Inc.</p><p>
<bold>Financial Disclosures for the previous 12 months</bold>: Stuart H. Isaacson has received honoraria for CME, consultant, research grants, and/or promotional speaker on behalf of AbbVie, Acadia, Acorda, Adamas Pharmaceuticals, Addex, Allergan, Amarantus, Auspex, Avid, Axovant, AZ Therapies, Biogen, Biotie, Britannia, Cynapsus, Eisai, Eli Lilly, GE Healthcare, Impax, Intec Pharma, Ipsen, Kyowa, Lundbeck, Medtronics, Merz, Michael J. Fox Foundation, Neurocrine, Neuroderm, NINDS/NIH, Parkinson Study Group, Pfizer, Pharma2B, Prothena, Roche, Sanofi, Shire, Sunovion, Teva, UCB, US WorldMeds, and XenoPort. Stanley Fahn has received consulting fees from Teva Pharmaceuticals, Intra&#x02010;Cellular Therapies, Inc, Adamas Pharmaceuticals, Retrophin Inc, PhotoPharmics, Kirkland &#x00026; Ellis, Sun Pharma Advanced Research Co. Ltd, and Kashiv Pharma, and received grant/research support from Smart Family Foundation. He has received personal fees from Springer Publishers for serving as co&#x02010;editor of <italic>Current Neurology and Neurosurgery Report</italic> (annual) and receives royalties from Elsevier Publishers for co&#x02010;authorship of book <italic>Principles and Practice of Movement Disorders</italic>. Rajesh Pahwa is receiving or has received honoraria or payments for consulting from AbbVie, Acadia, Acorda, Adamas Pharmaceuticals, Cynapsus, Impax, Lundbeck, Medtronic, Neurocrine, Sage, St Jude Medical, Teva Neuroscience, Medtronic, UCB, and US WorldMeds. He has received research grants from Acadia, Acorda, Adamas Pharmaceuticals, Avid, Biotie, Boston Scientific, Civitas, Cynapsus, Kyowa, NIH/NINDS, NPF, Pfizer, and PSG/University of Rochester. He has also served on the data monitoring committee for Ceregene. He has received personal compensation as the Co&#x02010;Editor&#x02010;in&#x02010;Chief of the International Journal of Neuroscience. Caroline M. Tanner is an employee of the University of California&#x02010;San Francisco and the San Francisco Veterans Affairs Medical Center and an intermittent employee of the Parkinson's Institute. She serves on the Scientific Advisory Boards of the Michael J. Fox Foundation and the National Spasmodic Dysphonia Association as a voluntary consultant and has provided paid consulting services to Ultragenyx Pharmaceuticals, Neurocrine Biosciences, Cynapsus Therapeutics, Sage Biometrics, and Adamas Pharmaceuticals. She has received compensation for serving on Data Monitoring Committees from Biotie Therapeutics, Voyager Therapeutics, and Intec Pharma. She receives grant support from the Michael J. Fox Foundation, the Parkinson's Disease Foundation, the Department of Defense, and the National Institutes of Health. Alberto J. Espay has received grant support from the National Institutes of Health, Great Lakes Neurotechnologies, and the Michael J. Fox Foundation; personal compensation as a consultant/scientific advisory board member for AbbVie, Teva, Impax, Acadia, Cynapsus, Lundbeck, and US WorldMeds; personal compensation as a member of the speaker bureau for AbbVie, Impax, Acadia, Lundbeck, and US WorldMeds; and publishing royalties from Lippincott Williams &#x00026; Wilkins, Cambridge University Press, and Springer. Claudia Trenkwalder reports personal fees from Mundipharma Research GmbH &#x00026; Co; payment for advisory board from Mundipharma Germany GmbH &#x00026; Co., UCB, Vifor, Britannia, Novartis; payment for lectures from UCB, Desitin, Britannia. Charles H. Adler has received consulting fees from Acadia, Acorda, Adamas, Extera Partners, Jazz, Lundbeck, Minerva, Neurocrine, Revance, Scion, and Sunovion, and received research funding from the Michael J. Fox Foundation for Parkinson's Research, and the NIH/NINDS. Rajiv Patni and Reed Johnson are employees and own stock in Adamas Pharmaceuticals.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="mdc312595-sup-0001"><caption><p>
<bold>Table S1</bold>. Efficacy results for MDS&#x02010;UPDRS Part IV (efficacy population).</p><p>
<bold>Table S2</bold>. Levodopa dose changes from baseline.</p></caption><media xlink:href="MDC3-5-183-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list content-type="cited-references"><title>References</title><ref id="mdc312595-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="mdc312595-cit-0001">
<string-name>
<surname>Van Den Eeden</surname>
<given-names>SK</given-names>
</string-name>, 
<string-name>
<surname>Tanner</surname>
<given-names>CM</given-names>
</string-name>, 
<string-name>
<surname>Bernstein</surname>
<given-names>AL</given-names>
</string-name>, et al. <article-title>Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity</article-title>. <source xml:lang="en">Am J Epidemiol</source>
<year>2003</year>;<volume>157</volume>(<issue>11</issue>):<fpage>1015</fpage>&#x02013;<lpage>1022</lpage>.
<pub-id pub-id-type="pmid">12777365</pub-id></mixed-citation></ref><ref id="mdc312595-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="mdc312595-cit-0002">
<string-name>
<surname>Connolly</surname>
<given-names>BS</given-names>
</string-name>, 
<string-name>
<surname>Lang</surname>
<given-names>AE</given-names>
</string-name>. <article-title>Pharmacological treatment of Parkinson disease: a review</article-title>. <source xml:lang="en">JAMA</source>
<year>2014</year>;<volume>311</volume>(<issue>16</issue>):<fpage>1670</fpage>&#x02013;<lpage>1683</lpage>.
<pub-id pub-id-type="pmid">24756517</pub-id></mixed-citation></ref><ref id="mdc312595-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="mdc312595-cit-0003">
<string-name>
<surname>Kordower</surname>
<given-names>JH</given-names>
</string-name>, 
<string-name>
<surname>Olanow</surname>
<given-names>CW</given-names>
</string-name>, 
<string-name>
<surname>Dodiya</surname>
<given-names>HB</given-names>
</string-name>, et al. <article-title>Disease duration and the integrity of the nigrostriatal system in Parkinson's disease</article-title>. <source xml:lang="en">Brain</source>
<year>2013</year>;<volume>136</volume>(<issue>Pt 8</issue>):<fpage>2419</fpage>&#x02013;<lpage>2431</lpage>.
<pub-id pub-id-type="pmid">23884810</pub-id></mixed-citation></ref><ref id="mdc312595-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="mdc312595-cit-0004">
<string-name>
<surname>Ferreira</surname>
<given-names>JJ</given-names>
</string-name>, 
<string-name>
<surname>Katzenschlager</surname>
<given-names>R</given-names>
</string-name>, 
<string-name>
<surname>Bloem</surname>
<given-names>BR</given-names>
</string-name>, et al. <article-title>Summary of the recommendations of the EFNS/MDS&#x02010;ES review on therapeutic management of Parkinson's disease</article-title>. <source xml:lang="en">Eur J Neurol</source>
<year>2013</year>;<volume>20</volume>(<issue>1</issue>):<fpage>5</fpage>&#x02013;<lpage>15</lpage>.
<pub-id pub-id-type="pmid">23279439</pub-id></mixed-citation></ref><ref id="mdc312595-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="mdc312595-cit-0005">
<string-name>
<surname>Ahlskog</surname>
<given-names>JE</given-names>
</string-name>, 
<string-name>
<surname>Muenter</surname>
<given-names>MD</given-names>
</string-name>. <article-title>Frequency of levodopa&#x02010;related dyskinesias and motor fluctuations as estimated from the cumulative literature</article-title>. <source xml:lang="en">Mov Disord</source>
<year>2001</year>;<volume>16</volume>(<issue>3</issue>):<fpage>448</fpage>&#x02013;<lpage>458</lpage>.
<pub-id pub-id-type="pmid">11391738</pub-id></mixed-citation></ref><ref id="mdc312595-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="mdc312595-cit-0006">
<string-name>
<surname>Olanow</surname>
<given-names>CW</given-names>
</string-name>, 
<string-name>
<surname>Stern</surname>
<given-names>MB</given-names>
</string-name>, 
<string-name>
<surname>Sethi</surname>
<given-names>K</given-names>
</string-name>. <article-title>The scientific and clinical basis for the treatment of Parkinson disease (2009)</article-title>. <source xml:lang="en">Neurology</source>
<year>2009</year>;<volume>72</volume>(<issue>21 Suppl 4</issue>):<fpage>S1</fpage>&#x02013;<lpage>136</lpage>.
</mixed-citation></ref><ref id="mdc312595-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="mdc312595-cit-0007">
<string-name>
<surname>Suh</surname>
<given-names>DC</given-names>
</string-name>, 
<string-name>
<surname>Pahwa</surname>
<given-names>R</given-names>
</string-name>, 
<string-name>
<surname>Mallya</surname>
<given-names>U</given-names>
</string-name>. <article-title>Treatment patterns and associated costs with Parkinson's disease levodopa induced dyskinesia</article-title>. <source xml:lang="en">J Neurol Sci</source>
<year>2012</year>;<volume>319</volume>(<issue>1&#x02013;2</issue>):<fpage>24</fpage>&#x02013;<lpage>31</lpage>.
<pub-id pub-id-type="pmid">22664154</pub-id></mixed-citation></ref><ref id="mdc312595-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="mdc312595-cit-0008">
<string-name>
<surname>Hechtner</surname>
<given-names>MC</given-names>
</string-name>, 
<string-name>
<surname>Vogt</surname>
<given-names>T</given-names>
</string-name>, 
<string-name>
<surname>Zollner</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Quality of life in Parkinson's disease patients with motor fluctuations and dyskinesias in five European countries</article-title>. <source xml:lang="en">Parkinsonism Relat Disord</source>
<year>2014</year>;<volume>20</volume>(<issue>9</issue>):<fpage>969</fpage>&#x02013;<lpage>974</lpage>.
<pub-id pub-id-type="pmid">24953743</pub-id></mixed-citation></ref><ref id="mdc312595-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="mdc312595-cit-0009">
<string-name>
<surname>Muller</surname>
<given-names>T</given-names>
</string-name>, 
<string-name>
<surname>Woitalla</surname>
<given-names>D</given-names>
</string-name>, 
<string-name>
<surname>Russ</surname>
<given-names>H</given-names>
</string-name>, 
<string-name>
<surname>Hock</surname>
<given-names>K</given-names>
</string-name>, 
<string-name>
<surname>Haeger</surname>
<given-names>DA</given-names>
</string-name>. <article-title>Prevalence and treatment strategies of dyskinesia in patients with Parkinson's disease</article-title>. <source xml:lang="en">J Neural Transm (Vienna)</source>
<year>2007</year>;<volume>114</volume>(<issue>8</issue>):<fpage>1023</fpage>&#x02013;<lpage>1026</lpage>.
<pub-id pub-id-type="pmid">17417738</pub-id></mixed-citation></ref><ref id="mdc312595-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="mdc312595-cit-0010">
<string-name>
<surname>Parsons</surname>
<given-names>CG</given-names>
</string-name>, 
<string-name>
<surname>Quack</surname>
<given-names>G</given-names>
</string-name>, 
<string-name>
<surname>Bresink</surname>
<given-names>I</given-names>
</string-name>, et al. <article-title>Comparison of the potency, kinetics and voltage&#x02010;dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo</article-title>. <source xml:lang="en">Neuropharmacology</source>
<year>1995</year>;<volume>34</volume>(<issue>10</issue>):<fpage>1239</fpage>&#x02013;<lpage>1258</lpage>.
<pub-id pub-id-type="pmid">8570022</pub-id></mixed-citation></ref><ref id="mdc312595-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="mdc312595-cit-0011">
<string-name>
<surname>Hubsher</surname>
<given-names>G</given-names>
</string-name>, 
<string-name>
<surname>Haider</surname>
<given-names>M</given-names>
</string-name>, 
<string-name>
<surname>Okun</surname>
<given-names>MS</given-names>
</string-name>. <article-title>Amantadine: the journey from fighting flu to treating Parkinson disease</article-title>. <source xml:lang="en">Neurology</source>
<year>2012</year>;<volume>78</volume>(<issue>14</issue>):<fpage>1096</fpage>&#x02013;<lpage>1099</lpage>.
<pub-id pub-id-type="pmid">22474298</pub-id></mixed-citation></ref><ref id="mdc312595-bib-0012"><label>12</label><mixed-citation publication-type="book" id="mdc312595-cit-0012">
<source xml:lang="en">Symmetrel (amantadine hydrochloride, USP) [prescribing information]</source>. <publisher-loc>Chadds Ford, PA</publisher-loc>: <publisher-name>Endo Pharmaceuticals Inc</publisher-name>; January <year>2009</year>.
</mixed-citation></ref><ref id="mdc312595-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="mdc312595-cit-0013">
<string-name>
<surname>Schwab</surname>
<given-names>RS</given-names>
</string-name>, 
<string-name>
<surname>England</surname>
<given-names>AC</given-names>, <suffix>Jr.</suffix>
</string-name>, 
<string-name>
<surname>Poskanzer</surname>
<given-names>DC</given-names>
</string-name>, 
<string-name>
<surname>Young</surname>
<given-names>RR</given-names>
</string-name>. <article-title>Amantadine in the treatment of Parkinson's disease</article-title>. <source xml:lang="en">JAMA</source>
<year>1969</year>;<volume>208</volume>(<issue>7</issue>):<fpage>1168</fpage>&#x02013;<lpage>1170</lpage>.
<pub-id pub-id-type="pmid">5818715</pub-id></mixed-citation></ref><ref id="mdc312595-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="mdc312595-cit-0014">
<string-name>
<surname>Parkes</surname>
<given-names>JD</given-names>
</string-name>, 
<string-name>
<surname>Zilkha</surname>
<given-names>KJ</given-names>
</string-name>, 
<string-name>
<surname>Marsden</surname>
<given-names>P</given-names>
</string-name>, 
<string-name>
<surname>Baxter</surname>
<given-names>RC</given-names>
</string-name>, 
<string-name>
<surname>Knill&#x02010;Jones</surname>
<given-names>RP</given-names>
</string-name>. <article-title>Amantadine dosage in treatment of Parkinson's disease</article-title>. <source xml:lang="en">Lancet (London, England)</source>
<year>1970</year>;<volume>1</volume>(<issue>7657</issue>):<fpage>1130</fpage>&#x02013;<lpage>1133</lpage>.
</mixed-citation></ref><ref id="mdc312595-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="mdc312595-cit-0015">
<string-name>
<surname>Thomas</surname>
<given-names>A</given-names>
</string-name>, 
<string-name>
<surname>Iacono</surname>
<given-names>D</given-names>
</string-name>, 
<string-name>
<surname>Luciano</surname>
<given-names>AL</given-names>
</string-name>, 
<string-name>
<surname>Armellino</surname>
<given-names>K</given-names>
</string-name>, 
<string-name>
<surname>Di Iorio</surname>
<given-names>A</given-names>
</string-name>, 
<string-name>
<surname>Onofrj</surname>
<given-names>M</given-names>
</string-name>. <article-title>Duration of amantadine benefit on dyskinesia of severe Parkinson's disease</article-title>. <source xml:lang="en">J Neurol Neurosurg Psychiatry</source>
<year>2004</year>;<volume>75</volume>(<issue>1</issue>):<fpage>141</fpage>&#x02013;<lpage>143</lpage>.
<pub-id pub-id-type="pmid">14707325</pub-id></mixed-citation></ref><ref id="mdc312595-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="mdc312595-cit-0016">
<string-name>
<surname>Hayden</surname>
<given-names>FG</given-names>
</string-name>, 
<string-name>
<surname>Gwaltney</surname>
<given-names>JM</given-names>, <suffix>Jr.</suffix>
</string-name>, 
<string-name>
<surname>Van de Castle</surname>
<given-names>RL</given-names>
</string-name>, 
<string-name>
<surname>Adams</surname>
<given-names>KF</given-names>
</string-name>, 
<string-name>
<surname>Giordani</surname>
<given-names>B</given-names>
</string-name>. <article-title>Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults</article-title>. <source xml:lang="en">Antimicrobial agents and chemotherapy</source>
<year>1981</year>;<volume>19</volume>(<issue>2</issue>):<fpage>226</fpage>&#x02013;<lpage>233</lpage>.
<pub-id pub-id-type="pmid">7347558</pub-id></mixed-citation></ref><ref id="mdc312595-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="mdc312595-cit-0017">
<string-name>
<surname>Fox</surname>
<given-names>SH</given-names>
</string-name>, 
<string-name>
<surname>Katzenschlager</surname>
<given-names>R</given-names>
</string-name>, 
<string-name>
<surname>Lim</surname>
<given-names>SY</given-names>
</string-name>, et al. <article-title>The Movement Disorder Society Evidence&#x02010;Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease</article-title>. <source xml:lang="en">Mov Disord</source>
<year>2011</year>;<volume>26</volume>
<issue>Suppl 3</issue>:<fpage>S2</fpage>&#x02013;<lpage>41</lpage>.
<pub-id pub-id-type="pmid">22021173</pub-id></mixed-citation></ref><ref id="mdc312595-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="mdc312595-cit-0018">
<string-name>
<surname>Pahwa</surname>
<given-names>R</given-names>
</string-name>, 
<string-name>
<surname>Factor</surname>
<given-names>SA</given-names>
</string-name>, 
<string-name>
<surname>Lyons</surname>
<given-names>KE</given-names>
</string-name>, et al. <article-title>Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence&#x02010;based review): report of the Quality Standards Subcommittee of the American Academy of Neurology</article-title>. <source xml:lang="en">Neurology</source>
<year>2006</year>;<volume>66</volume>(<issue>7</issue>):<fpage>983</fpage>&#x02013;<lpage>995</lpage>.
<pub-id pub-id-type="pmid">16606909</pub-id></mixed-citation></ref><ref id="mdc312595-bib-0019"><label>19</label><mixed-citation publication-type="miscellaneous" id="mdc312595-cit-0019">
<string-name>
<surname>Hauser</surname>
<given-names>RA</given-names>
</string-name>, 
<string-name>
<surname>Pahwa</surname>
<given-names>R</given-names>
</string-name>, 
<string-name>
<surname>Wargin</surname>
<given-names>W</given-names>
</string-name>, 
<string-name>
<surname>Souza&#x02010;Prien</surname>
<given-names>C</given-names>
</string-name>, 
<string-name>
<surname>McClure</surname>
<given-names>N</given-names>
</string-name>, 
<string-name>
<surname>Patni</surname>
<given-names>R</given-names>
</string-name>, 
<string-name>
<surname>Went</surname>
<given-names>GT</given-names>
</string-name>. Pharmacokinetics of ADS&#x02010;5102 [amantadine] extended release capsules administered once&#x02010;daily at bedtime for the treatment of dyskinesia. [Submitted].
</mixed-citation></ref><ref id="mdc312595-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="mdc312595-cit-0020">
<string-name>
<surname>Pahwa</surname>
<given-names>R</given-names>
</string-name>, 
<string-name>
<surname>Tanner</surname>
<given-names>CM</given-names>
</string-name>, 
<string-name>
<surname>Hauser</surname>
<given-names>RA</given-names>
</string-name>, et al. <article-title>ADS&#x02010;5102 (Amantadine) Extended&#x02010;Release Capsules for Levodopa&#x02010;Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial</article-title>. <source xml:lang="en">JAMA Neurol</source>
<year>2017</year>;<volume>74</volume>(<issue>8</issue>):<fpage>941</fpage>&#x02013;<lpage>949</lpage>.
<pub-id pub-id-type="pmid">28604926</pub-id></mixed-citation></ref><ref id="mdc312595-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="mdc312595-cit-0021">
<string-name>
<surname>Pahwa</surname>
<given-names>R</given-names>
</string-name>, 
<string-name>
<surname>Tanner</surname>
<given-names>CM</given-names>
</string-name>, 
<string-name>
<surname>Hauser</surname>
<given-names>RA</given-names>
</string-name>, et al. <article-title>Amantadine extended release for levodopa&#x02010;induced dyskinesia in Parkinson's disease (EASED Study)</article-title>. <source xml:lang="en">Mov Disord</source>
<year>2015</year>;<volume>30</volume>(<issue>6</issue>):<fpage>788</fpage>&#x02013;<lpage>795</lpage>.
<pub-id pub-id-type="pmid">25650051</pub-id></mixed-citation></ref><ref id="mdc312595-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="mdc312595-cit-0022">
<string-name>
<surname>Oertel</surname>
<given-names>W</given-names>
</string-name>, 
<string-name>
<surname>Eggert</surname>
<given-names>K</given-names>
</string-name>, 
<string-name>
<surname>Pahwa</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Randomized, placebo&#x02010;controlled trial of ADS&#x02010;5102 (amantadine) extended&#x02010;release capsules for levodopa&#x02010;induced dyskinesia in Parkinson's disease (EASE LID 3)</article-title>. <source xml:lang="en">Mov Disord</source>
<year>2017</year>.
</mixed-citation></ref><ref id="mdc312595-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="mdc312595-cit-0023">
<string-name>
<surname>Hauser</surname>
<given-names>RA</given-names>
</string-name>, 
<string-name>
<surname>Pahwa</surname>
<given-names>R</given-names>
</string-name>, 
<string-name>
<surname>Tanner</surname>
<given-names>CM</given-names>
</string-name>, et al. <article-title>ADS&#x02010;5102 (Amantadine) Extended&#x02010;Release Capsules for Levodopa&#x02010;Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open&#x02010;Label Safety Study</article-title>. <source xml:lang="en">J Parkinsons Dis</source>
<year>2017</year>;<volume>7</volume>(<issue>3</issue>):<fpage>511</fpage>&#x02013;<lpage>522</lpage>.
<pub-id pub-id-type="pmid">28777755</pub-id></mixed-citation></ref></ref-list></back></article>